We are live on ! Find out more
ADRX icon

ADARx Pharmaceuticals

14.00 USD
-0.20
1.41%
At close Updated Nov 16, 4:00 PM EST
Pre-market
After hours
14.00
0.00
0%
1 day
-1.41%
5 days
2.64%
1 month
-20.68%
3 months
-27.65%
6 months
-27.65%
Year to date
-27.65%
1 year
-27.65%
5 years
-27.65%
10 years
-27.65%
 

About: Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
Seeking Alpha
20 hours ago
ADARx Pharmaceuticals, Inc. (ADRX) Presents at UBS Global Biopharma Conference 2026 Transcript
ADARx Pharmaceuticals, Inc. ( ADRX ) UBS Global Biopharma Conference 2026 November 16, 2026 9:00 AM EST Company Participants Li Zhen - Co-Founder, President, CEO & Director Conference Call Participants Michael Yee - UBS Investment Bank, Research Division Presentation Michael Yee UBS Investment Bank, Research Division All right. Thank you, everyone.
ADARx Pharmaceuticals, Inc. (ADRX) Presents at UBS Global Biopharma Conference 2026 Transcript
Neutral
GlobeNewsWire
4 days ago
ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
– Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations into 2030 – – Advanced three Phase 2 clinical trials for agazisiran for the treatment of complement-mediated diseases – – Received Fast Track designation for onvuzosiran for HAE – SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (“ADARx” or the “Company”) (Nasdaq: ADRX), a late-clinical stage biotechnology company developing next-generation siRNA therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a summary of recent business highlights. “We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement.
ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
Neutral
GlobeNewsWire
8 days ago
ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, today announced that Zhen Li, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the UBS Global Biopharma Conference in London, UK on Monday, November 16, at 2:00 p.m.
ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
Neutral
GlobeNewsWire
1 month ago
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
Price charts implemented using Lightweight Charts™